Rexlemestrocel-L (MPC-150-IM) – Investigational Cell Therapy for Chronic Heart Failure

Generic Name: Rexlemestrocel-L (MPC-150-IM) | Developer: Mesoblast Limited | Indication: Chronic Heart Failure with Reduced Ejection Fraction (HFrEF)

Overview

Rexlemestrocel-L (MPC-150-IM) is an investigational allogeneic (donor-derived) mesenchymal precursor cell (MPC) therapy being developed by Mesoblast Limited for the treatment of chronic heart failure with reduced ejection fraction (HFrEF). Unlike Mesoblast’s other product remestemcel-L (for acute GVHD), rexlemestrocel-L is delivered directly into the heart muscle via transendocardial injection and aims to promote cardiac tissue repair, reduce inflammation, and improve heart function.

Key Facts

Developer: Mesoblast Limited (ASX: MSB, NASDAQ: MESO)
Product code: MPC-150-IM (Mesenchymal Precursor Cells – 150 million cells – IntraMyocardial)
Cell type: Allogeneic mesenchymal precursor cells (MPCs) derived from bone marrow
Indication: Chronic heart failure with reduced ejection fraction (HFrEF)
Delivery: Transendocardial injection (catheter-based delivery directly into heart muscle)
Dose: 150 million cells per treatment (single administration)
Stage: Phase III clinical trial (DREAM-HF) ongoing
FDA Designation: Breakthrough Therapy Designation (2019)

Heart Failure Background

What is Heart Failure with Reduced Ejection Fraction (HFrEF)?

Definition

Heart failure: Chronic condition where the heart cannot pump enough blood to meet the body’s needs
Reduced ejection fraction (HFrEF): Left ventricular ejection fraction (LVEF) ≤40%
Ejection fraction: Percentage of blood pumped out of the left ventricle with each heartbeat (normal: 50–70%)
Also called: Systolic heart failure, heart failure with reduced pump function

Causes

Coronary artery disease (CAD): Most common cause; heart attacks damage heart muscle
Hypertension: Chronic high blood pressure weakens heart over time
Cardiomyopathy: Disease of heart muscle (dilated, ischemic, etc.)
Valvular heart disease: Damaged heart valves increase workload
Myocarditis: Viral or autoimmune inflammation of heart muscle

Pathophysiology

Myocardial injury: Heart attack or chronic ischemia kills heart muscle cells (cardiomyocytes)
Scar tissue formation: Dead cells replaced by fibrotic scar tissue (non-contractile)
Ventricular remodeling: Heart chamber dilates and walls thin; pump function declines
Neurohormonal activation: Body compensates with adrenaline, angiotensin, aldosterone (initially helpful, ultimately harmful)
Progressive decline: Vicious cycle of worsening pump function, fluid retention, organ damage

Epidemiology & Burden

Prevalence

United States: ~6.5 million adults with heart failure; ~3 million with HFrEF
Global: ~64 million people with heart failure worldwide
Incidence: ~1 million new HF diagnoses annually (US)
Age: Prevalence increases with age; >10% of adults 70+ have HF

Clinical Impact

Symptoms: Shortness of breath, fatigue, exercise intolerance, fluid retention (edema), reduced quality of life
NYHA Classification:
- Class I: No symptoms with ordinary activity
- Class II: Symptoms with ordinary activity (mild limitation)
- Class III: Symptoms with less than ordinary activity (marked limitation)
- Class IV: Symptoms at rest (severe limitation)
Hospitalizations: ~1 million HF hospitalizations annually (US); major cost driver
Mortality: 5-year survival ~50% (worse than many cancers)

Economic Burden

US healthcare costs: ~$30 billion annually (hospitalizations, medications, devices)
Hospitalization cost: $10,000–30,000 per admission
Readmissions: 25% readmitted within 30 days; 50% within 6 months

Current Treatment Landscape

Pharmacologic Therapies (Guideline-Directed Medical Therapy – GDMT)

ACE inhibitors / ARBs: Reduce afterload, prevent remodeling (e.g., lisinopril, losartan)
Beta-blockers: Reduce heart rate, improve survival (e.g., carvedilol, metoprolol)
Mineralocorticoid receptor antagonists (MRAs): Reduce fluid retention, fibrosis (e.g., spironolactone, eplerenone)
ARNI (Angiotensin Receptor-Neprilysin Inhibitor): Entresto® (sacubitril/valsartan, Novartis) – reduces HF events and mortality
SGLT2 inhibitors: Farxiga® (dapagliflozin, AstraZeneca), Jardiance® (empagliflozin, Boehringer/Lilly) – reduce HF hospitalizations and mortality
Diuretics: Reduce fluid overload (e.g., furosemide)
Digoxin: Improves symptoms (limited mortality benefit)

Device Therapies

Implantable cardioverter-defibrillator (ICD): Prevents sudden cardiac death (arrhythmias)
Cardiac resynchronization therapy (CRT): Biventricular pacemaker improves pump coordination
Left ventricular assist device (LVAD): Mechanical pump for advanced HF (bridge to transplant or destination therapy)

Surgical Options

Heart transplantation: Definitive treatment but limited by donor availability (~3,500 transplants annually in US)
Coronary artery bypass grafting (CABG): Revascularization if ischemia present
Valve repair/replacement: If valvular disease contributing

Unmet Need

Despite advances (ARNI, SGLT2 inhibitors), many patients progress to advanced HF
Medications slow progression but don’t reverse underlying myocardial damage
Devices and transplant limited to small subset of patients
Need for regenerative therapy: Treatment that repairs damaged heart muscle, not just manages symptoms

Rexlemestrocel-L: Technology & Mechanism

Cell Type: Mesenchymal Precursor Cells (MPCs)

What are MPCs?

Definition: Early-stage mesenchymal stem cells with enhanced regenerative potential
Source: Bone marrow from healthy adult donors
Allogeneic: “Off-the-shelf” cells (not patient-specific); single donor → thousands of doses
Immune-privileged: Low immunogenicity; no HLA matching required
Difference from remestemcel-L: Earlier-stage cells with different expansion protocol; optimized for cardiac repair

Manufacturing

Donor selection: Healthy adults screened for infectious diseases, genetic disorders
Bone marrow harvest: Aspirate collected from donor
Cell isolation & expansion: MPCs isolated and cultured in bioreactors
Cryopreservation: Cells frozen and stored until use
Formulation: 150 million cells suspended in injection solution

Delivery Method: Transendocardial Injection

Procedure

Approach: Minimally invasive catheter-based procedure (no open-heart surgery)
Access: Catheter inserted through femoral artery (groin) and advanced to left ventricle
Mapping: Electromechanical mapping (NOGA® system) identifies damaged myocardium (scar tissue, viable but dysfunctional areas)
Injection: Catheter with retractable needle injects cells directly into heart muscle (10–15 injection sites)
Dose: 150 million cells total (distributed across injection sites)
Duration: ~2–3 hours (outpatient or overnight observation)
Anesthesia: Conscious sedation or general anesthesia

Advantages of Direct Injection

✅ Targeted delivery: Cells delivered directly to damaged heart tissue (vs IV infusion where most cells trapped in lungs)
✅ Higher local concentration: Maximizes therapeutic effect at site of injury
✅ Minimally invasive: Catheter-based (vs open-heart surgery)

Mechanisms of Action

1. Anti-Inflammatory

Reduce chronic inflammation: Heart failure characterized by persistent low-grade inflammation
Cytokine modulation: Decrease pro-inflammatory cytokines (TNF-α, IL-1β, IL-6); increase anti-inflammatory cytokines (IL-10, TGF-β)
Macrophage polarization: Shift macrophages from pro-inflammatory (M1) to pro-healing (M2) phenotype

2. Anti-Fibrotic

Reduce scar tissue: Inhibit fibroblast activation and collagen deposition
Matrix metalloproteinases (MMPs): MPCs secrete MMPs that break down excess collagen
Reverse remodeling: Reduce ventricular dilation, improve wall thickness

3. Pro-Angiogenic

New blood vessel formation: MPCs secrete VEGF, HGF, FGF that promote angiogenesis
Improve perfusion: Increase blood flow to ischemic heart muscle
Reduce ischemia: Better oxygen delivery to surviving cardiomyocytes

4. Cardioprotective

Prevent cardiomyocyte death: MPCs secrete anti-apoptotic factors (IGF-1, Akt pathway activation)
Improve cardiomyocyte function: Paracrine factors enhance contractility of surviving heart muscle cells
Mitochondrial function: Improve energy metabolism in stressed cardiomyocytes

5. Immunomodulation

Regulate immune response: Suppress excessive immune activation that contributes to HF progression
Promote regulatory T-cells (Tregs): Dampen chronic inflammation

Important Note: Paracrine Effects, Not Engraftment

MPCs do not become new heart muscle cells (cardiomyocytes)
Therapeutic effects mediated by secreted factors (growth factors, cytokines, extracellular vesicles)
MPCs present in heart for days to weeks, then cleared; effects persist long-term
Mechanism: “Hit and run” – cells trigger healing cascade, then disappear

Clinical Development: DREAM-HF Trial

Trial Overview

DREAM-HF (Definitive Randomized Evaluation of Allogeneic Mesenchymal Precursor Cells in Heart Failure)

Phase: Phase III, pivotal trial
Design: Randomized, double-blind, placebo-controlled, multicenter
Sponsor: Mesoblast Limited
Funding: Partially funded by NIH (National Institutes of Health) – validates scientific merit
ClinicalTrials.gov: NCT02032004

Patient Population

Inclusion Criteria (Key)

Diagnosis: Chronic heart failure with reduced ejection fraction (HFrEF)
LVEF: ≤35% (severely reduced pump function)
NYHA Class: II or III (symptomatic despite optimal medical therapy)
Guideline-directed medical therapy (GDMT): On stable, optimized HF medications for ≥3 months
Heart failure hospitalization: ≥1 HF hospitalization or urgent HF visit in past 12 months
Age: ≥18 years

Exclusion Criteria (Key)

Recent myocardial infarction (<3 months)
Planned cardiac surgery or revascularization
Severe valvular disease requiring intervention
Advanced kidney disease (eGFR <30 mL/min)
Active infection or malignancy

Enrollment

Target: 565 patients
Sites: ~60 centers in US, Canada, Europe
Status: Enrollment completed (2023)

Study Intervention

Treatment Arms

Rexlemestrocel-L: 150 million MPCs via transendocardial injection (single treatment) + GDMT
Placebo: Sham procedure (catheter insertion without cell injection) + GDMT
Randomization: 1:1 (rexlemestrocel-L : placebo)
Blinding: Double-blind (patients and investigators blinded to treatment assignment)

Sham Control Rationale

Placebo effect significant in HF trials (catheter procedure itself may have psychological benefit)
Sham procedure ensures blinding and controls for procedure-related effects
Ethical: All patients receive GDMT (standard of care)

Endpoints

Primary Endpoint

Composite endpoint: Time to first occurrence of:
- Recurrent heart failure events: HF hospitalizations + urgent HF visits requiring IV diuretics
- All-cause mortality
Analysis: Win ratio method (hierarchical composite endpoint)
Rationale: Captures both morbidity (HF events) and mortality; clinically meaningful

Secondary Endpoints

Cardiovascular mortality
Recurrent HF hospitalizations (frequency and duration)
Quality of life: Kansas City Cardiomyopathy Questionnaire (KCCQ) score
6-minute walk test: Exercise capacity
NYHA class: Functional status improvement
Left ventricular ejection fraction (LVEF): Echocardiographic assessment of pump function
NT-proBNP: Biomarker of heart failure severity

Safety Endpoints

Adverse events (AEs), serious adverse events (SAEs)
Procedure-related complications (bleeding, arrhythmias, perforation)
Ventricular arrhythmias (concern with any cardiac intervention)
Immune reactions (allogeneic cells)

Follow-Up

Duration

Primary endpoint: Assessed over ~30 months median follow-up (event-driven trial)
Clinic visits: Baseline, 1 month, 3 months, 6 months, then every 6 months
Assessments: Clinical status, echocardiography, quality of life, biomarkers, adverse events

Timeline & Status

Key Milestones

Trial initiation: 2014
Enrollment start: 2015
Enrollment completion: 2023 (565 patients enrolled)
Data readout: Expected 2024–2025 (event-driven; requires sufficient HF events/deaths)
Current status (2024): Ongoing; patients in follow-up phase; data monitoring committee (DMC) conducting interim analyses

Prior Clinical Data (Phase I/II)

Phase I/II Trials

Early Studies (2009–2015)

Design: Open-label, dose-escalation, safety and feasibility trials
Population: Chronic HFrEF patients (NYHA II-IV, LVEF <40%)
Doses tested: 25 million, 75 million, 150 million cells
Results:
- Safety: Well-tolerated; no serious procedure-related complications
- Feasibility: Transendocardial injection technically successful in >95% of patients
- Efficacy signals: Trends toward reduced HF events, improved quality of life, increased exercise capacity

Phase II Trial (2012–2016)

Design: Randomized, placebo-controlled, dose-ranging trial
Population: 60 patients with chronic HFrEF (NYHA II-III, LVEF ≤35%)
Arms: 25M cells, 75M cells, 150M cells, placebo (sham procedure)
Primary endpoint: Safety and tolerability
Secondary endpoints: HF events, quality of life, LVEF, biomarkers

Phase II Results

Safety: No dose-limiting toxicities; well-tolerated across all doses
HF events: Dose-dependent reduction in HF hospitalizations and urgent visits
- 150M cells: 65% reduction in HF events vs placebo (statistically significant)
- 75M cells: 50% reduction
- 25M cells: 30% reduction
Quality of life (KCCQ): Significant improvement with 150M dose
LVEF: Trend toward improvement (not statistically significant)
Reverse remodeling: MRI imaging showed reduced scar tissue, improved wall motion in 150M group
Conclusion: 150M cells selected for Phase III based on efficacy and safety

Mechanism Validation Studies

Cardiac MRI Substudy

Findings: Patients treated with rexlemestrocel-L showed:
- Reduced myocardial scar size (fibrosis)
- Improved regional wall motion (contractility)
- Reduced left ventricular volumes (reverse remodeling)
Interpretation: Supports anti-fibrotic and cardioprotective mechanisms

Biomarker Studies

NT-proBNP reduction: Biomarker of HF severity decreased in treated patients
Inflammatory markers: Reduction in CRP, IL-6 (anti-inflammatory effect)

Regulatory Status & Designations

FDA Breakthrough Therapy Designation (2019)

What is Breakthrough Therapy Designation?

Definition: FDA designation for drugs treating serious conditions with preliminary clinical evidence of substantial improvement over existing therapies
Benefits:
- More frequent FDA meetings and guidance
- Expedited review (Priority Review)
- Rolling submission of BLA (submit sections as completed)
- Senior FDA leadership involvement
Significance: FDA recognition that rexlemestrocel-L addresses unmet need and has promising data

Mesoblast’s Breakthrough Designation

Granted: May 2019
Basis: Phase II data showing 65% reduction in HF events with 150M dose
Indication: Chronic heart failure with reduced ejection fraction (HFrEF)

Regulatory Path Forward

If DREAM-HF Positive

BLA submission: 2025 (assuming data readout 2024–2025)
Priority Review: 6-month review (vs standard 10 months) due to Breakthrough Designation
Approval: Potential 2026 (if trial successful and no major issues)
Post-approval: Post-marketing surveillance, real-world evidence collection

If DREAM-HF Negative or Mixed

Subgroup analysis: Identify patient populations that benefit (e.g., specific NYHA class, LVEF range, biomarker levels)
Additional trials: May need confirmatory trial in selected subgroup
Regulatory discussions: FDA may require more data before approval

Market Opportunity

Target Population

United States

Total HF patients: ~6.5 million
HFrEF patients: ~3 million (LVEF ≤40%)
DREAM-HF eligible (LVEF ≤35%, NYHA II-III, recent HF event): ~1–1.5 million
Realistic addressable market: ~300,000–500,000 patients (subset willing/able to undergo catheter procedure, no contraindications)

Global

Total HF patients: ~64 million
HFrEF patients: ~30 million
Addressable market: ~3–5 million (developed markets with catheter lab infrastructure)

Pricing & Revenue Potential

Pricing Considerations

Comparators:
- LVAD (mechanical heart pump): $150,000–250,000 (device + surgery + complications)
- Heart transplant: $1–2 million (surgery + lifelong immunosuppression)
- Annual HF medications: $5,000–15,000 (ARNI, SGLT2i, etc.)
- HF hospitalization: $10,000–30,000 per admission
Value proposition: One-time treatment that reduces HF hospitalizations (saves $10,000–30,000 per avoided hospitalization)
Estimated pricing: $50,000–150,000 per treatment (one-time)
Rationale: Cost-effective if prevents 2–5 hospitalizations over patient lifetime

Peak Sales Potential (US)

Conservative scenario:
- Addressable market: 300,000 patients
- Market penetration: 10% (30,000 patients treated annually at steady state)
- Price: $75,000 per treatment
- Annual revenue: $2.25 billion
Optimistic scenario:
- Addressable market: 500,000 patients
- Market penetration: 20% (100,000 patients treated annually)
- Price: $100,000 per treatment
- Annual revenue: $10 billion
Analyst consensus: $1–3 billion peak sales (US) if approved

Global Peak Sales Potential

US + Europe + Japan + other developed markets: $3–8 billion peak sales
Timeline to peak: 5–7 years post-approval (gradual adoption, infrastructure build-out)

Reimbursement Considerations

Medicare/Medicaid (US)

Coverage: Likely covered if FDA-approved (HF is Medicare population)
Reimbursement level: Negotiated based on cost-effectiveness, budget impact
Cost-effectiveness: Must demonstrate QALY (quality-adjusted life year) benefit and reduced long-term costs (fewer hospitalizations)

Private Insurance (US)

Coverage: Likely covered with prior authorization
Criteria: May require failure of GDMT, specific LVEF/NYHA criteria, recent HF hospitalization

International

Europe: Health technology assessment (HTA) required; cost-effectiveness vs GDMT
Japan: National health insurance coverage likely if approved
Emerging markets: Limited coverage due to high cost

Competitive Landscape

Current Standard of Care

Pharmacologic Therapies

Entresto® (sacubitril/valsartan, Novartis): $7B+ annual sales; reduces HF events and mortality by ~20%
Farxiga® (dapagliflozin, AstraZeneca): $5B+ annual sales; reduces HF hospitalizations by ~30%
Jardiance® (empagliflozin, Boehringer/Lilly): Similar to Farxiga
Beta-blockers, ACE inhibitors, MRAs: Generic; low cost

Device Therapies

ICDs: Medtronic, Abbott, Boston Scientific (~$20,000–30,000 per device)
CRT-D: Biventricular pacemaker + defibrillator (~$30,000–40,000)
LVADs: HeartMate (Abbott), HVAD (Medtronic) (~$150,000–250,000 total cost)

Investigational Cell Therapies

Autologous Cell Therapies (Patient’s Own Cells)

Cardiopoietic stem cells: Patient’s bone marrow cells reprogrammed to cardiac lineage (Celyad, Belgium) – Phase III trials mixed results
Cardiac stem cells (CSCs): Cells isolated from patient’s heart tissue – multiple trials failed to show benefit; largely abandoned
Limitation: Autologous therapies require cell harvest from each patient (expensive, time-consuming, variable quality)

Allogeneic Cell Therapies (Donor Cells)

Rexlemestrocel-L (Mesoblast): Most advanced allogeneic MSC therapy for HF (Phase III)
Athersys (MultiStem): Allogeneic stem cells for stroke, ARDS; limited HF data
Pluristem (PLX-PAD): Placenta-derived cells for critical limb ischemia; exploring HF
Capricor (CAP-1002): Cardiac-derived cells (allogeneic); Phase II HF trials ongoing

Rexlemestrocel-L Competitive Advantages

✅ Most advanced: Only allogeneic MSC therapy in Phase III for HF
✅ Breakthrough Designation: FDA recognition of unmet need and promising data
✅ Allogeneic (off-the-shelf): Scalable, consistent quality vs autologous
✅ Phase II efficacy: 65% reduction in HF events
✅ NIH funding: Validates scientific merit

Future Competition

Gene Therapy

Approach: Deliver genes encoding growth factors, calcium-handling proteins, or other therapeutic proteins to heart
Status: Early-stage trials (Phase I/II)
Timeline: 5–10 years to approval (if successful)

Cardiac Regeneration (iPSC-Derived Cardiomyocytes)

Approach: Generate new heart muscle cells from induced pluripotent stem cells (iPSCs)
Status: Preclinical/early clinical (Japan, US)
Timeline: 10+ years to approval
Challenges: Engraftment, arrhythmia risk, scalability

Investment Considerations

For Mesoblast Shareholders

Bull Case 🐂

✅ Massive market opportunity: $3–8B peak sales potential (HF affects millions)
✅ Breakthrough Designation: FDA recognition; expedited review
✅ Phase II efficacy: 65% reduction in HF events (compelling data)
✅ NIH funding: Validates scientific merit; reduces development risk
✅ Unmet need: No regenerative therapy for HF; medications only slow progression
✅ Allogeneic advantage: Scalable manufacturing vs autologous therapies
✅ Multiple shots on goal: If HF succeeds, validates platform for other indications (back pain, etc.)

Bear Case 🐻

❌ Phase III execution risk: Cardiovascular trials notoriously difficult; high failure rate
❌ Endpoint complexity: Composite endpoint (HF events + mortality) challenging to power and interpret
❌ Competition from drugs: SGLT2 inhibitors (Farxiga, Jardiance) showing strong efficacy; raising bar for new therapies
❌ Procedure complexity: Transendocardial injection requires specialized catheter labs, trained operators (adoption barrier)
❌ Reimbursement uncertainty: High cost ($50,000–150,000); payers may resist coverage
❌ Financial distress: Mesoblast burning cash (~A$60–100M annually); frequent dilutive capital raises
❌ Timeline uncertainty: Data readout delayed multiple times; final results timing unclear
❌ Regulatory risk: Even if trial positive, FDA may require additional data (CMC issues with remestemcel-L suggest scrutiny)

Key Catalysts

Near-Term (2024–2025)

DREAM-HF data readout: Primary endpoint results (expected 2024–2025)
Interim analyses: Data Monitoring Committee (DMC) reviews; potential early stopping for efficacy or futility
Capital raises: Mesoblast will need funding to reach data readout and potential commercialization

Medium-Term (2026–2028)

BLA submission: If DREAM-HF positive (2025)
FDA approval: Potential 2026 (Priority Review due to Breakthrough Designation)
Commercial launch: US rollout; catheter lab training, reimbursement negotiations
International approvals: Europe (EMA), Japan (PMDA)

Valuation Impact

Scenario Analysis (Mesoblast Market Cap)

Current: ~US$300–500M (depressed due to cash burn, regulatory uncertainty)
DREAM-HF positive (base case): $3–5B (de-risks platform; commercial launch path clear)
Commercial success (bull case): $10–15B+ (peak sales $3–8B; platform validated for other indications)
DREAM-HF negative (bear case): $50–150M (bankruptcy risk; platform credibility damaged)

Risk-Adjusted NPV (Analyst Estimates)

Probability of success: 30–50% (Phase III cardiovascular trials historically ~50% success rate)
Peak sales (if approved): $1–3B (base case)
Time to peak: 2031–2033 (5–7 years post-approval)
Risk-adjusted value: $1–2B (probability-weighted)
Current market cap: $300–500M → potential 2–4x upside if trial succeeds

Key Takeaways

✅ Largest market opportunity for Mesoblast: HF affects millions; $3–8B peak sales potential
✅ Novel regenerative approach: First allogeneic cell therapy for chronic HF (if approved)
✅ Phase II efficacy: 65% reduction in HF events; reverse remodeling on MRI
✅ Breakthrough Designation: FDA recognition; expedited review pathway
✅ NIH funding: Validates scientific merit; reduces development risk
❌ Phase III execution risk: Cardiovascular trials difficult; 50% historical success rate
❌ Competition from drugs: SGLT2 inhibitors raising bar for new therapies
❌ Procedure complexity: Requires specialized catheter labs (adoption barrier)
❌ Financial stress: Mesoblast burning cash; dilution risk
⏳ Binary catalyst: DREAM-HF data readout (2024–2025) will determine fate of program and company

Related Terms

Heart failure with reduced ejection fraction (HFrEF) – Chronic HF with LVEF ≤40%
Mesenchymal precursor cells (MPCs) – Early-stage mesenchymal stem cells
Transendocardial injection – Catheter-based delivery of cells directly into heart muscle
NYHA class – New York Heart Association functional classification (I–IV)
LVEF (Left Ventricular Ejection Fraction) – Percentage of blood pumped out of left ventricle
GDMT (Guideline-Directed Medical Therapy) – Optimal HF medications per guidelines
Breakthrough Therapy Designation – FDA designation for expedited development/review
DREAM-HF – Phase III trial of rexlemestrocel-L for chronic HF
Allogeneic cell therapy – Donor-derived cells (off-the-shelf)
Reverse remodeling – Improvement in heart structure/function (reduced dilation, increased LVEF)

Disclaimer: This information is for educational purposes only and does not constitute medical or investment advice. Rexlemestrocel-L is investigational; not approved for any indication. Mesoblast stock is high-risk, speculative investment with significant risks including Phase III trial failure, financial distress, and dilution. DYOR and consult professionals before making medical or investment decisions.

Mesoblast Investor Relations: investorcentre.mesoblast.com

DREAM-HF Trial: ClinicalTrials.gov NCT02032004

NIH Funding: NIH RePORTER (Search: Mesoblast, DREAM-HF)

Related Topics: Rexlemestrocel-L, MPC-150-IM, Heart Failure, HFrEF, Mesenchymal Stem Cells, Cell Therapy, Regenerative Medicine, DREAM-HF, Mesoblast, Transendocardial Injection, Breakthrough Therapy, Cardiovascular Disease, Clinical Trials

Uninformed Investors